{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:06:18Z","timestamp":1792087578978,"version":"4.4.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009731","name":"Sichuan Provincial Youth Science and Technology Fund","doi-asserted-by":"publisher","award":["2023YFS0182"],"award-info":[{"award-number":["2023YFS0182"]}],"id":[{"id":"10.13039\/501100009731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009731","name":"Sichuan Provincial Youth Science and Technology Fund","doi-asserted-by":"publisher","award":["00402053A29RU"],"award-info":[{"award-number":["00402053A29RU"]}],"id":[{"id":"10.13039\/501100009731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioadv.2025.214600","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:24:13Z","timestamp":1763184253000},"page":"214600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeted inhibition of colorectal cancer by nano-dihydroartemisinin liposomes: Insights into the disruption of ABCG2 and BCL2 leading to induction of oxidative stress and metabolic disorder"],"prefix":"10.1016","volume":"180","author":[{"given":"Jun-Feng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuowei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunshui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengliang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bioadv.2025.214600_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bioadv.2025.214600_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000543921","article-title":"Colorectal Cancer: epidemiology, risk factors, and public health strategies","volume":"106","author":"Matsuda","year":"2025","journal-title":"Digestion"},{"key":"10.1016\/j.bioadv.2025.214600_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/ijph.2024.1606736","article-title":"The influence of sex and\/or gender on the occurrence of colorectal Cancer in the general population in developed countries: a scoping review","volume":"69","author":"Martinez","year":"2024","journal-title":"Int. J. Public Health"},{"issue":"10449","key":"10.1016\/j.bioadv.2025.214600_bb0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"9927","key":"10.1016\/j.bioadv.2025.214600_bb0025","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.bioadv.2025.214600_bb0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41571-023-00766-x","article-title":"Gut microbiota in colorectal cancer development and therapy","volume":"20","author":"Wong","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bioadv.2025.214600_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"11\u221212","key":"10.1016\/j.bioadv.2025.214600_bb0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1101\/gad.348226.120","article-title":"Genetic and biological hallmarks of colorectal cancer","volume":"35","author":"Li","year":"2021","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/ijms18010197","article-title":"Colorectal carcinoma: a general overview and future perspectives in colorectal Cancer","volume":"18","author":"M\u00e1rmol","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/cells13030245","article-title":"Update on targeted therapy and immunotherapy for metastatic colorectal Cancer","volume":"13","author":"Underwood","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioadv.2025.214600_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102112","article-title":"Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities","volume":"91","author":"Mauri","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioadv.2025.214600_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bioadv.2025.214600_bb0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal Cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3892\/ol.2022.13261","article-title":"Management of chemotherapy dose intensity for metastatic colorectal cancer","volume":"23","author":"Chu","year":"2022","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.bioadv.2025.214600_bb0075","doi-asserted-by":"crossref","first-page":"G223","DOI":"10.1152\/ajpgi.00212.2014","article-title":"Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity","volume":"308","author":"Stojanovska","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bioadv.2025.214600_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104544","article-title":"Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist","volume":"204","author":"Svec","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioadv.2025.214600_bb0085","article-title":"5-fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition","volume":"137","author":"Sethy","year":"2021","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacological reports: PR"},{"key":"10.1016\/j.bioadv.2025.214600_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101170","article-title":"Autophagy in cancer development, immune evasion, and drug resistance","volume":"78","author":"Niu","year":"2025","journal-title":"Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.bioadv.2025.214600_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.bioadv.2025.214600_bb0105","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.bioadv.2025.214600_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, Oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.bioadv.2025.214600_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176013","article-title":"Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery","volume":"958","author":"Davodabadi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioadv.2025.214600_bb0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.7150\/ijbs.50364","article-title":"Dihydroartemisinin: a potential natural anticancer drug","volume":"17","author":"Dai","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"21","key":"10.1016\/j.bioadv.2025.214600_bb0125","doi-asserted-by":"crossref","first-page":"31413","DOI":"10.18632\/oncotarget.8920","article-title":"Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt\/\u03b2-catenin signaling","volume":"7","author":"Tong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioadv.2025.214600_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.722331","article-title":"Dihydroartemisinin: a potential drug for the treatment of malignancies and inflammatory diseases","volume":"11","author":"Yu","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bioadv.2025.214600_bb0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.canlet.2013.09.035","article-title":"Dihydroartemisinin induces autophagy by suppressing NF-\u03baB activation","volume":"343","author":"Hu","year":"2014","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.bioadv.2025.214600_bb0140","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/molecules29163886","article-title":"Artemisinin and its derivatives as potential anticancer agents","volume":"29","author":"Wen","year":"2024","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0145","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10495-011-0580-6","article-title":"Interruption of the MEK\/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo","volume":"16","author":"Gao","year":"2011","journal-title":"Apoptosis: an international journal on programmed cell death"},{"key":"10.1016\/j.bioadv.2025.214600_bb0150","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/OTT.S297785","article-title":"Dihydroartemisinin as a sensitizing agent in Cancer therapies","volume":"14","author":"Li","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bioadv.2025.214600_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151854","article-title":"Exploring combinations of dihydroartemisinin for cancer therapy: a comprehensive review","volume":"765","author":"Rani","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bioadv.2025.214600_bb0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajps.2022.04.005","article-title":"Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: a review","volume":"17","author":"Wong","year":"2022","journal-title":"Asian journal of pharmaceutical sciences"},{"issue":"8","key":"10.1016\/j.bioadv.2025.214600_bb0165","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3390\/ijms23084249","article-title":"Nanoliposomes in Cancer therapy: marketed products and current clinical trials","volume":"23","author":"Tal\u00e9ns-Visconti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioadv.2025.214600_bb0170","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2174\/1871520616666151116121821","article-title":"Nanoliposome is a promising carrier of protein and peptide biomolecule for the treatment of Cancer","volume":"16","author":"Kumar Giri","year":"2016","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.bioadv.2025.214600_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116674","article-title":"Borneol and lactoferrin dual-modified crocetin-loaded nanoliposomes enhance neuroprotection in HT22 cells and brain targeting in mice","volume":"276","author":"Tong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioadv.2025.214600_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108729","article-title":"Dihydroartemisinin suppresses metastatic potential and induces apoptosis in gastric adenocarcinoma: an integrative experimental and computational analysis revealing inhibition of MMP14 and promotion of oxidative stress","volume":"163","author":"Cao","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioadv.2025.214600_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177964","article-title":"Cuproptosis induced by curcumin interfering with proliferation and energy metabolism in colorectal cancer: 3D tumor model and computational simulations reveal curcumin inhibition of HSPD1 and CALCOCO2","volume":"1003","author":"Cao","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioadv.2025.214600_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2022.109131","article-title":"Molecular docking and molecular dynamics simulation study the mechanism of progesterone in the treatment of spinal cord injury","volume":"188","author":"Yang","year":"2022","journal-title":"Steroids"},{"key":"10.1016\/j.bioadv.2025.214600_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1601908","article-title":"Mechanistic insights curcumin\u2019s anti-inflammatory in pancreatic cancer: experimental and computational evidence implicating IL1B interference via IL10RA upregulation and NLRP3\/TLR3 downregulation","volume":"13","author":"Cao","year":"2025","journal-title":"Frontiers in cell and developmental biology"},{"issue":"10","key":"10.1016\/j.bioadv.2025.214600_bb0200","first-page":"6042","article-title":"Up-regulated and hypomethylated genes are causative factors and diagnostic markers of osteoporosis","volume":"15","author":"Minbo","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bioadv.2025.214600_bb0205","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6285099","article-title":"Interference of interleukin-1\u03b2 mediated by lentivirus promotes functional recovery of spinal cord contusion injury in rats via the PI3K\/AKT1 signaling pathway","volume":"2022","author":"Cao","year":"2022","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0210","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13046-018-0980-3","article-title":"IMPDH2 promotes colorectal cancer progression through activation of the PI3K\/AKT\/mTOR and PI3K\/AKT\/FOXO1 signaling pathways","volume":"37","author":"Duan","year":"2018","journal-title":"Journal of experimental & clinical cancer research: CR"},{"issue":"8","key":"10.1016\/j.bioadv.2025.214600_bb0215","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.21037\/tcr-23-186","article-title":"Abnormal genetic and epigenetic patterns of m6A regulators associated with tumor microenvironment in colorectal cancer","volume":"12","author":"Ren","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bioadv.2025.214600_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108264","article-title":"Insights into curcumin\u2019s anticancer activity in pancreatic ductal adenocarcinoma: experimental and computational evidence targeting HRAS, CCND1, EGFR and AKT1","volume":"157","author":"Cao","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0225","article-title":"Dihydroartemisinin regulates the apoptosis and growth of colorectal cancer by suppressing DPYSL2 and increasing TF and ACHE. July 2024Food","volume":"61","author":"Zhang","year":"2024","journal-title":"Bioscience"},{"key":"10.1016\/j.bioadv.2025.214600_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105746","article-title":"Rapamycin improves the survival of epilepsy model cells by blocking phosphorylation of mTOR base on computer simulations and cellular experiments","volume":"176","author":"Li","year":"2024","journal-title":"Neurochem. Int."},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12967-018-1540-5","article-title":"CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin","volume":"16","author":"Xu","year":"2018","journal-title":"J. Transl. Med."},{"issue":"23","key":"10.1016\/j.bioadv.2025.214600_bb0240","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1002\/1873-3468.13947","article-title":"The ABCG2\/BCRP transporter and its variants - from structure to pathology","volume":"594","author":"Sarkadi","year":"2020","journal-title":"FEBS Lett."},{"issue":"21\u221222","key":"10.1016\/j.bioadv.2025.214600_bb0245","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1007\/s00018-021-03901-y","article-title":"Multidrug efflux transporter ABCG2: expression and regulation","volume":"78","author":"Kukal","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.bioadv.2025.214600_bb0250","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1042\/BST20180145","article-title":"ABCG2: does resolving its structure elucidate the mechanism?","volume":"46","author":"Kapoor","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bioadv.2025.214600_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114628","article-title":"Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development","volume":"241","author":"Moinul","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioadv.2025.214600_bb0260","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.3390\/ijms26136119","article-title":"ABCG2 transporter: from structure to function-current insights and open questions","volume":"26","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2025.214600_bb0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2017.10.004","article-title":"BCRP\/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications","volume":"147","author":"Hira","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bioadv.2025.214600_bb0270","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/ijms22062786","article-title":"Medically important alterations in transport function and trafficking of ABCG2","volume":"22","author":"Homolya","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioadv.2025.214600_bb0275","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/bph.14991","article-title":"3D structure of the transporter ABCG2-what\u2019s new?","volume":"177","author":"Eckenstaler","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioadv.2025.214600_bb0280","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17425255.2019.1591373","article-title":"ABCG2\/BCRP: variants, transporter interaction profile of substrates and inhibitors","volume":"15","author":"Safar","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.bioadv.2025.214600_bb0285","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/ijms18091926","article-title":"Implications of ABCG2 expression on irinotecan treatment of colorectal Cancer patients: a review","volume":"18","author":"Nielsen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pharmthera.2007.02.001","article-title":"The role of transporters in cellular heme and porphyrin homeostasis","volume":"114","author":"Krishnamurthy","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioadv.2025.214600_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115883","article-title":"Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7\/ADR cells by inhibiting BCRP function and mediating apoptosis","volume":"436","author":"Chang","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0300","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/15548627.2016.1155009","article-title":"A role for ABCG2 beyond drug transport: regulation of autophagy","volume":"12","author":"Ding","year":"2016","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016007","article-title":"Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance","volume":"6","author":"Goler-Baron","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2025.214600_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.615729","article-title":"Identification of specific trafficking defects of naturally occurring variants of the human ABCG2 transporter","volume":"9","author":"Bartos","year":"2021","journal-title":"Frontiers in cell and developmental biology"},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0315","first-page":"651","article-title":"Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia","volume":"24","author":"Hu","year":"2019","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"9","key":"10.1016\/j.bioadv.2025.214600_bb0320","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4155\/fmc.13.71","article-title":"ABCG2: recent discovery of potent and highly selective inhibitors","volume":"5","author":"Lecerf-Schmidt","year":"2013","journal-title":"Future Med. Chem."},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0325","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/pharmrev.120.000025","article-title":"ABCB1 and ABCG2 regulation at the blood-brain barrier: potential new targets to improve brain drug delivery","volume":"75","author":"Schulz","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioadv.2025.214600_bb0330","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jare.2024.03.029","article-title":"Punicalagin attenuates hyperuricemia via restoring hyperuricemia-induced renal and intestinal dysfunctions","volume":"69","author":"Han","year":"2025","journal-title":"J. Adv. Res."},{"issue":"2","key":"10.1016\/j.bioadv.2025.214600_bb0335","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejps.2012.06.011","article-title":"PXR and NF-\u03baB correlate with the inducing effects of IL-1\u03b2 and TNF-\u03b1 on ABCG2 expression in breast cancer cell lines","volume":"47","author":"Malekshah","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.bioadv.2025.214600_bb0340","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bcp.2012.01.033","article-title":"Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells","volume":"83","author":"Goler-Baron","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0345","first-page":"1678","article-title":"The PI3K\/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bioadv.2025.214600_bb0350","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/138920111795163995","article-title":"The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival","volume":"12","author":"Krishnamurthy","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0355","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CAD.0000000000000315","article-title":"Gemcitabine upregulates ABCG2\/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells","volume":"27","author":"Sun","year":"2016","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bioadv.2025.214600_bb0360","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.acr.2014.10.004","article-title":"Lipid regulation of the ABCB1 and ABCG2 multidrug transporters","volume":"125","author":"Heged\u00fcs","year":"2015","journal-title":"Adv. Cancer Res."},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0365","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.113.088609","article-title":"Molecular pharmacology of ABCG2 and its role in chemoresistance","volume":"84","author":"Stacy","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"46","key":"10.1016\/j.bioadv.2025.214600_bb0370","doi-asserted-by":"crossref","first-page":"17775","DOI":"10.1021\/acs.jafc.3c02797","article-title":"Coffee leaf tea extracts improve hyperuricemia nephropathy and its associated negative effect in gut microbiota and amino acid metabolism in rats","volume":"71","author":"Zhou","year":"2023","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioadv.2025.214600_bb0380","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging"},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0385","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0390","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond - mitochondrial performance in apoptosis","volume":"285","author":"Pe\u00f1a-Blanco","year":"2018","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0395","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in Cancer biology and therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu. Rev. Pathol."},{"issue":"9","key":"10.1016\/j.bioadv.2025.214600_bb0400","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41556-024-01429-4","article-title":"Mitochondria and cell death","volume":"26","author":"Glover","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioadv.2025.214600_bb0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mito.2014.06.002","article-title":"Mitochondrial ROS and involvement of Bcl-2 as a mitochondrial ROS regulator","volume":"19 Pt A","author":"Chong","year":"2014","journal-title":"Mitochondrion"},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0410","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.stemcr.2015.04.004","article-title":"High glutathione and glutathione peroxidase-2 levels mediate cell-type-specific DNA damage protection in human induced pluripotent stem cells","volume":"4","author":"Dannenmann","year":"2015","journal-title":"Stem Cell Rep."},{"issue":"12","key":"10.1016\/j.bioadv.2025.214600_bb0415","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1080\/15548627.2024.2389474","article-title":"Role of AMBRA1 in mitophagy regulation: emerging evidence in aging-related diseases","volume":"20","author":"Di Rienzo","year":"2024","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0420","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbcan.2017.06.004","article-title":"BCL2: a promising cancer therapeutic target","volume":"1868","author":"Radha","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bioadv.2025.214600_bb0425","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fcell.2020.00467","article-title":"Mitophagy, mitochondrial homeostasis, and cell fate","volume":"8","author":"Ma","year":"2020","journal-title":"Frontiers in cell and developmental biology"},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0430","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/15548627.2015.1017192","article-title":"The role of STAT3 in autophagy","volume":"11","author":"You","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.bioadv.2025.214600_bb0435","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.canlet.2021.08.020","article-title":"Bcl2-associated athanogene 4 promotes the invasion and metastasis of gastric cancer cells by activating the PI3K\/AKT\/NF-\u03baB\/ZEB1 axis","volume":"520","author":"Jiang","year":"2021","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.bioadv.2025.214600_bb0440","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pros.22857","article-title":"Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes","volume":"74","author":"Calastretti","year":"2014","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.bioadv.2025.214600_bb0445","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/cbin.11840","article-title":"Calycosin suppresses colorectal cancer progression by targeting ER\u03b2, upregulating PTEN, and inhibiting PI3K\/Akt signal pathway","volume":"46","author":"Zhu","year":"2022","journal-title":"Cell Biol. Int."},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0450","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000709","article-title":"Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K\/Akt\/mTOR pathway","volume":"30","author":"Zhou","year":"2019","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"10.1016\/j.bioadv.2025.214600_bb0455","first-page":"541","article-title":"Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival","volume":"37","author":"Bratton","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0460","first-page":"867","article-title":"Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3","volume":"28","author":"Rubenstein","year":"2014","journal-title":"In vivo (Athens, Greece)"},{"issue":"24","key":"10.1016\/j.bioadv.2025.214600_bb0465","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/febs.14122","article-title":"Control of cell death and mitochondrial fission by ERK1\/2 MAP kinase signalling","volume":"284","author":"Cook","year":"2017","journal-title":"FEBS J."},{"issue":"9","key":"10.1016\/j.bioadv.2025.214600_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.693","article-title":"Cell death pathways: molecular mechanisms and therapeutic targets for cancer","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"8","key":"10.1016\/j.bioadv.2025.214600_bb0475","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1074\/jbc.M308938200","article-title":"Bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1\/ERK2 activity","volume":"279","author":"Trisciuoglio","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioadv.2025.214600_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2021.106016","article-title":"Emerging strategies for sensitization of therapy resistant tumors toward cancer therapeutics by targeting the Bcl-2 family, TGF-\u03b2, Wnt\/\u03b2-catenin, RASSF and miRNA regulated signaling pathways","volume":"137","author":"Veerasamy","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.bioadv.2025.214600_bb0485","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/15548627.2020.1752548","article-title":"Autophagy in the physiological endometrium and cancer","volume":"17","author":"Devis-Jauregui","year":"2021","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.bioadv.2025.214600_bb0490","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1002\/cam4.3840","article-title":"miR-140-3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2","volume":"10","author":"Liu","year":"2021","journal-title":"Cancer Med."},{"issue":"9\u201310","key":"10.1016\/j.bioadv.2025.214600_bb0495","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10495-024-01977-y","article-title":"Mitophagy in health and disease. Molecular mechanisms, regulatory pathways, and therapeutic implications","volume":"29","author":"D\u2019Arcy","year":"2024","journal-title":"Apoptosis: an international journal on programmed cell death"},{"issue":"1\u20132","key":"10.1016\/j.bioadv.2025.214600_bb0500","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis: an international journal on programmed cell death"},{"issue":"11","key":"10.1016\/j.bioadv.2025.214600_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2022.119330","article-title":"Molecular insights into peroxisome homeostasis and peroxisome biogenesis disorders","volume":"1869","author":"Fujiki","year":"2022","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.bioadv.2025.214600_bb0510","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12957-016-0769-9","article-title":"Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer","volume":"14","author":"Li","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bioadv.2025.214600_bb0515","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/IJN.S349426","article-title":"Advances in Nanoliposomes for the diagnosis and treatment of liver Cancer","volume":"17","author":"Li","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioadv.2025.214600_bb0525","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2014.05.029","article-title":"Sustained-release from nanocarriers: a review","volume":"193","author":"Natarajan","year":"2014","journal-title":"J. Control. Release"}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950825004273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950825004273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:55:33Z","timestamp":1765212933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950825004273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":104,"alternative-id":["S2772950825004273"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2025.214600","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted inhibition of colorectal cancer by nano-dihydroartemisinin liposomes: Insights into the disruption of ABCG2 and BCL2 leading to induction of oxidative stress and metabolic disorder","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2025.214600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"214600"}}